Journal of Clinical Endocrinology & Metabolism, Vol 79, 561-567, Copyright © 1994 by Endocrine Society

ARTICLES

Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men

CJ Bagatell, JR Heiman, AM Matsumoto, JE Rivier and WJ Bremner
Medical Service, Seattle Veterans Affairs Medical Center, Washington.

In addition to their use as replacement therapy for hypogonadal males, androgens, particularly testosterone (T), are being explored as potential hormonal male contraceptive agents, alone or in combination with other compounds. Androgens have regulatory effects on a variety of physiological systems in addition to gonadotropin secretion and spermatogenesis. Therefore, as hormonal contraceptive regiments that alter serum T levels are explored, it is important to evaluate their effects on these aspects of normal male physiology. The effects of exogenous T on suppression of spermatogenesis in 19 healthy men were recently compared, using a T dosage of 200 mg im/week for 20 weeks. Before treatment, the men were evaluated during a 3-month pretreatment period, and after treatment, they were followed for 4-6 months or until their sperm counts normalized. Because of the lack of information regarding the effects of exogenous T on nonreproductive physiology, we examined the effects of high-dose T on plasma lipids, calcium metabolism, and sexual behavior in our subjects. Mean serum T and estradiol levels increased significantly during the treatment period. Plasma high-density lipoprotein (HDL) cholesterol levels decreased significantly within the first month and remained suppressed during the duration of T administration. At the end of the treatment period, mean plasma HDL cholesterol had decreased by 13 +/- 2% (P < 0.05); plasma levels of HDL2, HDL3, and apoprotein AI also decreased significantly; mean levels of low density lipoprotein cholesterol and triglycerides were unchanged. After 1 month of the recovery period, plasma HDL levels had returned to the baseline range. Serum calcium levels decreased slightly during treatment; this decrease was statistically significant. Urinary calcium excretion did not change. Mean levels of serum intact PTH increased by 84 +/- 17% (P < 0.05) during T administration; in contrast, 25-hydroxyvitamin D levels decreased by 16 +/- 4% (P < 0.05), and 1,25-dihydroxyvitamin D levels did not change significantly. All markers of calcium metabolism returned to baseline during the posttreatment period. Little change was found in self-reported sexual and aggressive behaviors during the study. There was a trend toward increased arousal and spontaneous erections during T administration, but this did not reach statistical significance. Frequency of sexual intercourse, masturbation, and kissing and fondling did not change, nor was the subjects' satisfaction in their relationships affected by T administration. Mean body weight increased by 4.0 +/- 0.5 kg. Approximately half the men noted mild acne. Body weight and acne symptoms returned to baseline during the recovery period.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				S. T. Page, J. K. Amory, and W. J. Bremner Advances in Male Contraception Endocr. Rev., June 1, 2008; 29(4): 465 - 493. [Abstract] [Full Text] [PDF]

				M.C. Meriggiola, S. Cerpolini, W.J. Bremner, M.T. Mbizvo, K.M. Vogelsong, G. Martorana, and G. Pelusi Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men Hum. Reprod., August 1, 2006; 21(8): 2033 - 2040. [Abstract] [Full Text] [PDF]

				A. Armagan, N. N. Kim, I. Goldstein, and A. M. Traish Dose-Response Relationship Between Testosterone and Erectile Function: Evidence for the Existence of a Critical Threshold J Androl, July 1, 2006; 27(4): 517 - 526. [Abstract] [Full Text] [PDF]

				J Bancroft The endocrinology of sexual arousal J. Endocrinol., September 1, 2005; 186(3): 411 - 427. [Abstract] [Full Text] [PDF]

				C. J. Hay, B. M. Brady, M. Zitzmann, K. Osmanagaoglu, P. Pollanen, D. Apter, F. C. W. Wu, R. A. Anderson, E. Nieschlag, P. Devroey, et al. A Multicenter Phase IIb Study of a Novel Combination of Intramuscular Androgen (Testosterone Decanoate) and Oral Progestogen (Etonogestrel) for Male Hormonal Contraception J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2042 - 2049. [Abstract] [Full Text] [PDF]

				T. A. Henriques, J. Huang, S. S. D'Souza, A. Daugherty, and L. A. Cassis Orchidectomy, But Not Ovariectomy, Regulates Angiotensin II-Induced Vascular Diseases in Apolipoprotein E-Deficient Mice Endocrinology, August 1, 2004; 145(8): 3866 - 3872. [Abstract] [Full Text] [PDF]

				D. B. O'Connor, J. Archer, and F. C. W. Wu Effects of Testosterone on Mood, Aggression, and Sexual Behavior in Young Men: A Double-Blind, Placebo-Controlled, Cross-Over Study J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2837 - 2845. [Abstract] [Full Text] [PDF]

				Y.-q. Gu, J.-s. Tong, D.-z. Ma, X.-h. Wang, D. Yuan, W.-h. Tang, and W. J. Bremner Male Hormonal Contraception: Effects of Injections of Testosterone Undecanoate and Depot Medroxyprogesterone Acetate at Eight-Week Intervals in Chinese Men J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2254 - 2262. [Abstract] [Full Text] [PDF]

				M. C. Meriggiola, A. Costantino, S. Cerpolini, W. J. Bremner, D. Huebler, A. M. Morselli-Labate, B. Kirsch, A. Bertaccini, C. Pelusi, and G. Pelusi Testosterone Undecanoate Maintains Spermatogenic Suppression Induced by Cyproterone Acetate Plus Testosterone Undecanoate in Normal Men J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5818 - 5826. [Abstract] [Full Text] [PDF]

				K. K. Lee, N. Berman, G. M. Alexander, L. Hull, R. S. Swerdloff, and C. Wang A Simple Self-Report Diary for Assessing Psychosexual Function in Hypogonadal Men J Androl, September 1, 2003; 24(5): 688 - 698. [Abstract] [Full Text] [PDF]

				M. C. Meriggiola, T. M.M. Farley, and M. T. Mbizvo A Review of Androgen-Progestin Regimens for Male Contraception J Androl, July 1, 2003; 24(4): 466 - 483. [Full Text] [PDF]

				R. A. Anderson, A. M. Wallace, N. Sattar, N. Kumar, and K. Sundaram Evidence for Tissue Selectivity of the Synthetic Androgen 7{alpha}-Methyl-19-Nortestosterone in Hypogonadal Men J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2784 - 2793. [Abstract] [Full Text] [PDF]

				K. L. Herbst, J. K. Amory, J. D. Brunzell, H. A. Chansky, and W. J. Bremner Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1112 - E1118. [Abstract] [Full Text] [PDF]

				F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF]

				K. L. Herbst, B. D. Anawalt, J. K. Amory, A. M. Matsumoto, and W. J. Bremner The Male Contraceptive Regimen of Testosterone and Levonorgestrel Significantly Increases Lean Mass in Healthy Young Men in 4 Weeks, but Attenuates a Decrease in Fat Mass Induced by Testosterone Alone J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1167 - 1173. [Abstract] [Full Text] [PDF]

				F. R. Sattler, E. T. Schroeder, M. P. Dube, S. V. Jaque, C. Martinez, P. J. Blanche, S. Azen, and R. M. Krauss Metabolic effects of nandrolone decanoate and resistance training in men with HIV Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1214 - E1222. [Abstract] [Full Text] [PDF]

				R.A. Anderson, Z.M. van der Spuy, O.A. Dada, S.K. Tregoning, P.M. Zinn, O.A. Adeniji, T.A. Fakoya, K.B. Smith, and D.T. Baird Investigation of hormonal male contraception in African men: suppression of spermatogenesis by oral desogestrel with depot testosterone Hum. Reprod., November 1, 2002; 17(11): 2869 - 2877. [Abstract] [Full Text] [PDF]

				M. C. Meriggiola, A. Costantino, W. J. Bremner, and A. M. Morselli-Labate Higher Testosterone Dose Impairs Sperm Suppression Induced by a Combined Androgen-Progestin Regimen J Androl, September 1, 2002; 23(5): 684 - 690. [Abstract] [Full Text] [PDF]

				A. M. Kenny, K. M. Prestwood, C. A. Gruman, G. Fabregas, B. Biskup, and G. Mansoor Effects of Transdermal Testosterone on Lipids and Vascular Reactivity in Older Men With Low Bioavailable Testosterone Levels J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M460 - 465. [Abstract] [Full Text]

				M. C. Meriggiola, W. J. Bremner, A. Costantino, A. Bertaccini, A. M. Morselli-Labate, D. Huebler, G. Kaufmann, M. Oettel, and C. Flamigni Twenty-One Day Administration of Dienogest Reversibly Suppresses Gonadotropins and Testosterone in Normal Men J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2107 - 2113. [Abstract] [Full Text] [PDF]

				P. Kunelius, O. Lukkarinen, M. L. Hannuksela, O. Itkonen, and J. S. Tapanainen The Effects of Transdermal Dihydrotestosterone in the Aging Male: A Prospective, Randomized, Double Blind Study J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1467 - 1472. [Abstract] [Full Text] [PDF]

				A. M. Matsumoto Andropause: Clinical Implications of the Decline in Serum Testosterone Levels With Aging in Men J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2002; 57(2): M76 - 99. [Full Text]

				A. Vermeulen Androgen Replacement Therapy in the Aging Male--A Critical Evaluation J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2380 - 2390. [Full Text] [PDF]

				C. W. Martin, S. C. Riley, D. Everington, N. P. Groome, R. A. Riemersma, D. T. Baird, and R. A. Anderson Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men Hum. Reprod., July 1, 2000; 15(7): 1515 - 1524. [Abstract] [Full Text] [PDF]

				H. G. Pope Jr, E. M. Kouri, and J. I. Hudson Effects of Supraphysiologic Doses of Testosterone on Mood and Aggression in Normal Men: A Randomized Controlled Trial Arch Gen Psychiatry, February 1, 2000; 57(2): 133 - 140. [Abstract] [Full Text] [PDF]

				P. Alexandersen, J. Haarbo, I. Byrjalsen, H. Lawaetz, and C. Christiansen Natural Androgens Inhibit Male Atherosclerosis : A Study in Castrated, Cholesterol-Fed Rabbits Circ. Res., April 16, 1999; 84(7): 813 - 819. [Abstract] [Full Text] [PDF]

				S. N. Seidman and B. T. Walsh Testosterone and Depression in Aging Men Am J Geriatr Psychiatry, February 1, 1999; 7(1): 18 - 33. [Abstract] [Full Text]

				F. C. W. Wu, R. Balasubramanian, T. M. T. Mulders, and H. J. T. Coelingh-Bennink Oral Progestogen Combined with Testosterone as a Potential Male Contraceptive: Additive Effects between Desogestrel and Testosterone Enanthate in Suppression of Spermatogenesis, Pituitary-Testicular Axis, and Lipid Metabolism J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 112 - 122. [Abstract] [Full Text]

				D. E. Cummings, N. Kumar, C. W. Bardin, K. Sundaram, and W. J. Bremner Prostate-Sparing Effects in Primates of the Potent Androgen 7{alpha}-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4212 - 4219. [Abstract] [Full Text]

				J. P. Bilezikian, A. Morishima, J. Bell, and M. M. Grumbach Increased Bone Mass as a Result of Estrogen Therapy in a Man with Aromatase Deficiency N. Engl. J. Med., August 27, 1998; 339(9): 599 - 603. [Full Text] [PDF]

				P. S. Kwon, T. Maurer, P. E. LeBoit, R. Aly, and T. G. Berger Hormone-Induced Acneiform Eruption in Human Immunodeficiency Virus Disease Arch Dermatol, March 1, 1998; 134(3): 374 - 376. [Full Text] [PDF]

				R. R. Hajjar, F. E. Kaiser, and J. E. Morley Outcomes of Long-Term Testosterone Replacement in Older Hypogonadal Males: A Retrospective Analysis J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3793 - 3796. [Abstract] [Full Text] [PDF]

				S. Arslanian and C. Suprasongsin Testosterone Treatment in Adolescents with Delayed Puberty: Changes in Body Composition, Protein, Fat, and Glucose Metabolism J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3213 - 3220. [Abstract] [Full Text] [PDF]

				A. von Eckardstein, S. Kliesch, E. Nieschlag, A. Chirazi, G. Assmann, and H. M. Behre Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a) J. Clin. Endocrinol. Metab., October 1, 1997; 82(10): 3367 - 3372. [Abstract] [Full Text] [PDF]

				J. D. Wagner, L. Zhang, J. K. Williams, T. C. Register, D. M. Ackerman, B. Wiita, T. B. Clarkson, and M. R. Adams Esterified Estrogens With and Without Methyltestosterone Decrease Arterial LDL Metabolism in Cynomolgus Monkeys Arterioscler. Thromb. Vasc. Biol., December 1, 1996; 16(12): 1473 - 1480. [Abstract] [Full Text]

				C. J. Bagatell and W. J. Bremner Androgens in Men -- Uses and Abuses N. Engl. J. Med., March 14, 1996; 334(11): 707 - 715. [Full Text] [PDF]

				D. Pratico and G. A. FitzGerald Testosterone and Thromboxane : Of Muscles, Mice, and Men Circulation, June 1, 1995; 91(11): 2694 - 2698. [Full Text]